U.S. markets open in 6 hours 56 minutes
  • S&P Futures

    3,297.25
    -36.50 (-1.09%)
     
  • Dow Futures

    27,096.00
    -312.00 (-1.14%)
     
  • Nasdaq Futures

    11,183.25
    -154.50 (-1.36%)
     
  • Russell 2000 Futures

    1,488.80
    -18.20 (-1.21%)
     
  • Crude Oil

    38.89
    -0.40 (-1.02%)
     
  • Gold

    1,891.30
    -11.90 (-0.63%)
     
  • Silver

    23.88
    -0.57 (-2.33%)
     
  • EUR/USD

    1.1733
    -0.0012 (-0.11%)
     
  • 10-Yr Bond

    0.6450
    0.0000 (0.00%)
     
  • Vix

    26.27
    +0.08 (+0.31%)
     
  • GBP/USD

    1.2836
    -0.0024 (-0.18%)
     
  • USD/JPY

    105.5730
    -0.0820 (-0.08%)
     
  • BTC-USD

    10,744.72
    -99.49 (-0.92%)
     
  • CMC Crypto 200

    230.32
    +0.65 (+0.28%)
     
  • FTSE 100

    5,897.50
    -30.43 (-0.51%)
     
  • Nikkei 225

    23,185.12
    -353.98 (-1.50%)
     

Verastem Oncology to Present at Upcoming Investor Conferences

Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to developing and commercializing new medicines for patients battling cancer, today announced that management will present virtually at the following upcoming investor conferences:

  • H.C. Wainwright 22nd Annual Global Investment Conference on Monday, September 14, 2020 at 1:30 p.m. Eastern Time

  • Cantor Virtual Global Healthcare Conference on Thursday, September 17, 2020 at 3:20 p.m. Eastern Time

A live webcast of the presentations will be available on the investors section of the Company’s website at www.verastem.com. An archived presentation will be available for 90 days.

About Verastem Oncology

Verastem Oncology (Nasdaq: VSTM) is a development-stage biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition and focal adhesion kinase (FAK) inhibition. For more information, please visit www.verastem.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200910005802/en/

Contacts

Verastem Oncology Contacts:

Investors:
John Doyle
Vice President, Investor Relations & Finance
+1 781-469-1546
jdoyle@verastem.com

Media:
Lisa Buffington
Corporate Communications
+1 781-292-4205
lbuffington@verastem.com